Novel hexahydrocyclopentapyrrol-indolemethanimine as highly potent α-glucosidase inhibitors; design, biological evaluation, and computational insights

  • Bioorg Chem. 2025 Oct:165:108922. doi: 10.1016/j.bioorg.2025.108922.
Shiva Molaei  1 Shahrzad Javanshir  2 Mohammad Mahdavi  3 Aida Iraji  4
Affiliations
  • 1. Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran; University of Science and Technology, Tehran, Iran.
  • 2. Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran; University of Science and Technology, Tehran, Iran. Electronic address: [email protected].
  • 3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences, Iran.
  • 4. Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: [email protected].
Abstract

A series of novel hexahydrocyclopentapyrrol-indolemethanimine derivatives were synthesized and evaluated for their α-glucosidase inhibitory activity. All compounds demonstrated promising inhibition with IC50 values in the range of 1.05 to 95.60 μM, which compounds 9i, 9l, and 9o demonstrated the best potential anti-α-glucosidase activity (IC50 of 1.05, 14.45, and 17.13 μM, respectively), surpassing the efficacy of the positive control, acarbose (IC50 = 750.0 ± 2.0 μM). The kinetic studies showed that the most potent derivative (compound 9i) inhibits competitively, which suggests its direct interaction at the active site of α-glucosidase (Kᵢ value of 0.39 μM). Molecular docking studies demonstrated that compound 9i effectively forms hydrogen bonds and hydrophobic interactions with the enzyme active-site catalytic residues. Molecular docking studies also corroborated this idea by demonstrating that compound 9i effectively formed hydrogen bonds and hydrophobic interactions with the enzyme active-site catalytic residues. Molecular dynamics simulations further highlighted the formation and stable nature of the enzyme-inhibitor complex over a 100-ns trajectory with minimum fluctuation, suggesting strong and stable binding. These results are indicative of the fact that this new scaffold could be considered as a lead for further development of α-glucosidase inhibitors in the management of Type 2 Diabetes.

Keywords
Diabetes mellitus; Hexahydrocyclopentapyrrolo; Molecular dynamics; α-Glucosidase.
Products